학술논문
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Document Type
Article
Author
Source
In The American Journal of Cardiology 1 September 2014 114(5):711-715
Subject
Language
ISSN
0002-9149